AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual Healthcare Conference

AMAG Pharmaceuticals, Inc. to Participate in the Cowen and Company 34th Annual
Healthcare Conference

WALTHAM, Mass., Feb. 27, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc.
(Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive
officer, will present at the Cowen and Company 34^th Annual Healthcare
Conference on Monday, March 3, 2014 at 4:10 p.m. ET in Boston. The session
will include a company presentation followed by a question and answer session,
in which the company's business and financial outlook, strategy and growth
prospects will be discussed.

A live audio webcast of the discussion will be accessible through the
Investors section of the company's website at www.amagpharma.com. Following
the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc.
website for 30 days.

About AMAG

AMAG Pharmaceuticals, Inc. is a rapidly growing, specialty pharmaceutical
company, supported by a talented and passionate workforce. AMAG currently
markets Feraheme® (ferumoxytol) Injection and MuGard® Mucoadhesive Oral Wound
Rinse in the United States. Along with driving organic growth of its products,
AMAG intends to expand its portfolio with additional commercial-stage
specialty products. The company is seeking complementary products that
leverage the company's commercial footprint and focus on hematology and
oncology centers and hospital infusion centers. The company's primary goal is
to bring to market therapies that provide clear benefits and improve patients'
lives. For additional company information, please visit www.amagpharma.com.

AMAG Pharmaceuticals and Feraheme are registered trademarks of AMAG
Pharmaceuticals, Inc. MuGard is a registered trademark of Access
Pharmaceuticals, Inc.

CONTACT: AMAG Pharmaceuticals, Inc. Contact:
         Amy Sullivan, 617-498-3303

AMAG Pharmaceuticals logo
 
Press spacebar to pause and continue. Press esc to stop.